Evidence map›Paper›PMID 25090196›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2014

Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol.

Ming Yang, Samuel K Lai, Tao Yu, Ying-Ying Wang, Christina Happe, Weixi Zhong, Michael Zhang, Abraham Anonuevo, Colleen Fridley, Amy Hung and 2 more

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 116 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Engineering the Mucus Barrier.Annual review of biomedical engineering · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ming YangCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Samuel K LaiCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA; Center for Cancer Nanotechnology Excellence, Institute for NanoBioTechnology, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA.
Tao YuCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Ying-Ying WangCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Christina HappeDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA.
Weixi ZhongDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA.
Michael ZhangDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA.
Abraham AnonuevoDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA.
Colleen FridleyDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA.
Amy HungCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA.
Jie FuCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA.
Justin HanesCenter for Nanomedicine, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287, USA; Center for Cancer Nanotechnology Excellence, Institute for NanoBioTechnology, Johns Hopkins University, 3400 N Charles Street, Baltimore, MD 21218, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21287, USA. Electronic address: hanes@jhu.edu.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

ValidationU54CA151838 · NCI · JOHNS HOPKINS UNIVERSITY · PI POMPER, MARTIN G, SEARSON, PETER C · 2010 to 2014
$11.9M
Mucus-penetrating nanoparticles for sustained microbicide deliveryR33AI079740 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S. · 2010 to 2012
$1.4M
Mucus Penetrating Particles for Rectal MicrobicidesR33AI094519 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CONE, RICHARD, HANES, JUSTIN S. · 2013 to 2015
$1.4M
Mucus penetrating nanoparticles for early stage cervical cancerR01CA140746 · NCI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S. · 2009 to 2010
$665k
Polymer nanoparticles that cross mucusR21HL089816 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S. · 2008 to 2009
$449k
Mucus Penetrating Particles for Rectal MicrobicidesR21AI094519 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CONE, RICHARD, HANES, JUSTIN S. · 2011 to 2012
$440k
NCI NIH HHS R01 CA140746NCI NIH HHS R01CA140746NCI NIH HHS U54 CA151838NCI NIH HHS U54CA151838NHLBI NIH HHS R21 HL089816NHLBI NIH HHS R21HL089816NIAID NIH HHS R21 AI094519NIAID NIH HHS R21AI094519NIAID NIH HHS R33 AI079740NIAID NIH HHS R33AI079740NIAID NIH HHS R33 AI094519
6 · The paper itself

Abstract

Therapeutic nanoparticles must rapidly penetrate the mucus secretions lining the surfaces of the respiratory, gastrointestinal and cervicovaginal tracts to efficiently reach the underlying tissues. Whereas most polymeric nanoparticles are highly mucoadhesive, we previously discovered that a dense layer of low MW polyethylene glycol (PEG) conferred a sufficiently hydrophilic and uncharged surface to effectively minimize mucin-nanoparticle adhesive interactions, allowing well-coated particles to rapidly diffuse through human mucus. Here, we sought to investigate the influence of surface coating by polyvinyl alcohol (PVA), a relatively hydrophilic and uncharged polymer routinely used as a surfactant to formulate drug carriers, on the transport of nanoparticles in fresh human cervicovaginal mucus. We found that PVA-coated polystyrene (PS) particles were immobilized, with speeds at least 4000-fold lower in mucus than in water, regardless of the PVA molecular weight or incubation concentration tested. Nanoparticles composed of poly(lactide-co-glycolide) (PLGA) or diblock copolymers of PEG-PLGA were similarly immobilized when coated with PVA (slowed 29,000- and 2500-fold, respectively). PVA coatings could not be adequately removed upon washing, and the residual PVA prevented sufficient coating with Pluronic F127 capable of reducing particle mucoadhesion. In contrast to PVA-coated particles, the similar sized PEG-coated formulations were slowed only ~6- to 10-fold in mucus compared to in water. Our results suggest that incorporating PVA in the particle formulation process may lead to the formation of mucoadhesive particles for many nanoparticulate systems. Thus, alternative methods for particle formulation, based on novel surfactants or changes in the formulation process, should be identified and developed in order to produce mucus-penetrating particles for mucosal applications.

Indexed as

AdhesivenessCervix MucusCoated Materials, BiocompatibleDrug CarriersHumansNanoparticlesPolyestersPolyethylene GlycolsPolyglactin 910Polyvinyl AlcoholCoated Materials, BiocompatibleDrug CarriersPolyesterspolyethylene glycol-poly(lactide-co-glycolide)Polyethylene GlycolsPolyglactin 910Polyvinyl AlcoholBiodegradable polymersDrug deliveryMucoadhesionMucus-penetrating particlesSurfactant

Identifiers

PMID25090196
PMCPMC4194208
OpenAlexW2027522130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.